A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Durvalumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms SKYSCRAPER-03
- Sponsors Roche
- 21 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI205423).
- 12 Aug 2020 New trial record